7
Participants
Start Date
December 31, 2019
Primary Completion Date
October 12, 2022
Study Completion Date
July 1, 2025
Letetresgene autoleucel
Letetresgene autoleucel will be administered.
Cyclophosphamide
Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Fludarabine
Fludarabine will be used as a lymphodepleting chemotherapy.
Memorial Sloan Kettering cancer center, New York
University of Pittsburgh, Hillman Cancer centre, Pittsburgh
Ircss Istituto Clinico Humanitas, Romano di Lombardia
Fondazione IRCCS Instituto Nazionale Dei Tumori, Milan
Virginia Commonwealth University, Richmond
Duke University Medical Center, Durham
Hospital Universitario Fundación Jiménez Díaz, Madrid
Mayo Clinic Jacksonville, Jacksonville
CHU de Bordeaux GH Sud Hôpital Haut Lévêque, Pessac
Tennessee Oncology, Nashville
Hospital Virgen Del Rocio, Seville
Ohio State University-Columbus, Columbus
University of Michigan Medical Center, Ann Arbor
Froedtert Hospital, Milwaukee
Minnesota Oncology Hematology, Minneapolis
Mayo Clinic Rochester, Rochester
University of Chicago, Chicago
Washington University, St Louis
Centre Léon Bérard, Lyon
Sarah Cannon Research Institute, Denver
University of Utah, Salt Lake City
City of Hope National Medical Center, Duarte
Stanford Hospital and Clinics, Stanford
Oregon Health and Science University, Portland
University of Iowa College of Medicine, Iowa City
Dana Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
University Of Texas Southwestern Medical Center, Dallas
University of Texas Southwestern Medical Center, Dallas
Fred Hutchinson Cancer Research Center, Seattle
CIUSSS de L'Est-De-Lile-De-Montreal, Montreal
Princess Margaret Cancer Centre, Toronto
The Netherlands Cancer Institute, Amsterdam
Hospital Santa Creu Y Sant Pau, Barcelona
Ico Duran y Reynals l'Hospitalet de Llobrega, Hospitalet de Llobregat, Barcelona
Royal Marsden Hospital, London
University College Hospital-London, London
Christie Hospital NHS Foundation Trust, Manchester
Lead Sponsor
Adaptimmune
INDUSTRY